SCHEMBL2176287

SCHEMBL2176287

C[C@H]1C(=O)N(C)C(=NC(=O)O)N(C(C)(C)C)[C@]1(C)c1cccc(Br)c1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 1/20 0.35
HCAR2 Q8TDS4 1/20 0.35
HSD11B1 P28845 1/20 0.31
CHRNA1 P02708 1/20 0.31
CHRNG P07510 1/20 0.31
CHRNB1 P11230 1/20 0.31
CHRNB2 P17787 1/20 0.31
SLC6A2 P23975 1/20 0.31
CHRNB4 P30926 1/20 0.31
SLC6A4 P31645 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
SLC6A3 Q01959 1/20 0.31
CHRND Q07001 1/20 0.31
ALDH1A1 P00352 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2964904 0.75 HCAR3 (0.37) HCAR3HCAR2HSD11B1CHRNA1CHRNG
SCHEMBL2964902 0.75 HCAR3 (0.37) HCAR3HCAR2HSD11B1CHRNA1CHRNG
SCHEMBL14576457 0.71 HCAR3 (0.35) HCAR3HCAR2CHRNA1CHRNGCHRNB1
SCHEMBL2176282 0.69 RORC (0.33) HCAR3HCAR2CHRNA1CHRNGCHRNB1
SCHEMBL7581890 0.66 CHRNA1 (0.37) HCAR3HCAR2HSD11B1CHRNA1CHRNG
SCHEMBL17707721 0.64 HCAR3 (0.39) HCAR3HCAR2HSD11B1CHRNA1CHRNG
SCHEMBL17707720 0.64 HCAR3 (0.39) HCAR3HCAR2HSD11B1CHRNA1CHRNG
SCHEMBL21981814 0.64 HCAR3 (0.39) HCAR3HCAR2HSD11B1CHRNA1CHRNG
SCHEMBL29031880 0.59 HCAR3 (0.44) HCAR3HCAR2ALDH1A1MEN1KMT2A
SCHEMBL30472345 0.59 HCAR3 (0.44) HCAR3HCAR2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110218194-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS Schering Corporation & Pharmacopeia Drug Discovery Inc. (US) 2011-09-08 US disclosed
US-7973067-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2011-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218194-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS CHRM1, CHRM2, PRSS1 HCAR3 1751/4885HCAR2 2333/4885HSD11B1 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.